CX3CL1 polyclonal Antibody | BS60619

CX3CL1 polyclonal Antibody | BS60619 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB

Application Range: WB: 1:500~1:1000

Background: Chemokines are members of a superfamily of inducible, secreted, proinflammatory cytokines. Members of the chemokine family exhibit 20-50% homology in their predicted amino acid sequences and are divided into four subfamilies. In the subfamily designated C-C or β, the first two cysteines are adjacent. In the C-X-C or a subfamily, the first two of four cysteine residues are separated by a single amino acid. C subfamily members, also designated γ chemokines, lack the first and third cysteine residues of the conserved motif. Chemokines in these three subfamilies are small, secreted proteins with molecular weights ranging from 7-15 kDa. Fractalkine, also designated neurotactin, is the first characterized member of a fourth chemokine subfamily. Fractalkine contains a novel C-X3-C motif in which the first two cysteines are separated by three amino acid residues. Fractalkine mRNA has been detected in brain and heart and is upregulated in microglia and endothelial cells by inflammatory signals. The protein can exist both as a membranebound form and as a chemotactic soluble form.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: CX3CL1 polyclonal Antibody detects endogenous levels of CX3CL1 protein.

Molecular Weight: ~ 42 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Fractalkine; C-X3-C motif chemokine 1; CX3C membrane-anchored chemokine; Neurotactin; Small-inducible cytokine D1; ed into the following chain:Processed fractalkine; CX3CL1; FKN; NTT; SCYD1

Immunogen: A synthetic peptide corresponding to residues in Human CX3CL1

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: